Detalhe da pesquisa
1.
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Allergy;
78(1): 233-243, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35899469
2.
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Allergy;
78(8): 2157-2167, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37059696
3.
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma.
Ann Allergy Asthma Immunol;
130(3): 298-304, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36509407
4.
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Ann Allergy Asthma Immunol;
130(2): 206-214.e2, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36332763
5.
Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
J Asthma;
60(9): 1767-1774, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36876957
6.
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Allergy;
77(4): 1231-1244, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34459002
7.
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Mult Scler;
28(4): 573-582, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34378446
8.
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Mult Scler;
26(8): 955-963, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31144568
9.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler;
26(14): 1866-1876, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31762387
10.
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Mult Scler;
25(12): 1605-1617, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30289355
11.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet;
390(10102): 1585-1594, 2017 Sep 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28755782
12.
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500â cells·µL-1.
Eur Respir J;
59(6)2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35487538
13.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord;
18(1): 174, 2017 04 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28449657
14.
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.
Eur Respir J;
58(4)2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34326187
15.
Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.
Ther Innov Regul Sci;
58(3): 495-504, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38315407
16.
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
J Allergy Clin Immunol Pract;
11(4): 1213-1220.e2, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36535524
17.
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
J Immunol Res;
2023: 9943584, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37901346
18.
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
J Asthma Allergy;
16: 249-260, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36915284
19.
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
Laryngoscope;
132(2): 259-264, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34817082
20.
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
J Allergy Clin Immunol Pract;
10(11): 2916-2924.e4, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36028446